Opus Genetics, Inc. Common Stock

IRDNASDAQ • USD
3.98 USD
↘ 0.08 (1.97%)AT CLOSE (03:59 PM EST)
4.03
↗ 0.05 (1.36%)
POST MARKET (AS OF 04:15 PM EST)
Post Market
AS OF 04:15 PM EST
4.03
↗ 0.05 (1.36%)
🔴Market: CLOSED

IRD is currently priced at $3.98. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, IRD trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 13, 2026.

Open?$4.15
High?$4.17
Low?$3.80
Prev. Close?$4.06
Volume?747.4K
Avg. Volume?1.4M
VWAP?$3.93
Rel. Volume?0.53x
Bid / Ask
Bid?$3.90 × 200
Ask?$4.17 × 100
Spread?$0.27
Midpoint?$4.04
Valuation & Ratios
Market Cap?384.7M
Shares Out?96.7M
Float?62.3M
Float %?75.3%
P/E Ratio?N/A
P/B Ratio?10.01
EPS?-$1.41
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Employees
28
Market Cap
384.7M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-11-06
Address
8 DAVIS DRIVE
DURHAM, NC 27713
Phone: (984) 884-6030
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
35
Short Sent.?
55
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.45Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?17.45%High
Short Interest?10.9M
Days to Cover?8.4
Free Float62.3M
Avg Daily Volume1.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?9.65Strong
Quick Ratio?9.65Strong
Cash Ratio?9.05Strong
Debt/Equity?0.90Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
19
10.01HIGH▾
P/S?
Peers
100
S&P
3
48.61HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
41.73HIGH▾
Returns & Efficiency
ROE?
S&P
3
-355.6%WEAK▾
ROA?
S&P
3
-143.4%WEAK▾
Cash Flow & Enterprise
FCF?$-48735000
Enterprise Value?$330.2M
Fundamentals ratios updated end of day